Sector Alpha Week of 2026-08-05
Sector Alpha — machine-written from the numbers · Data as of 2026-08-05

Diversified Healthcare Trust

DHC
Real Estate · REIT - Healthcare Facilities

Diversified Healthcare Trust's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.

Biggest watch item: the price is already 47 weeks into its uptrend — timing risk, not thesis risk.

The price is in a confirmed uptrend (47 weeks in). Underneath, the last four quarters read mixed. What settles it: the next one or two quarters of delivery.

Price
$8.8
+169.1% 1Y
Revenue (Mar 26)
$0.4 B
−5.1% YoY
Profit (Mar 26)
$−0.0 B
Operating margin
0.0%
+10.3 pp YoY
ROE
−16%
FY25
ROIC
−0.8%
vs WACC 10.9% → −11.7 pp
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Diversified Healthcare Trust trades at $8.8, in a confirmed uptrend and 47 weeks into that stage. That is +29.8% against its own 200-day average. It sits at 89% of a 52-week range of $3 to $9. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (1 week and counting).

Today the stock is in a confirmed uptrend — week 47 of stage 2. At $8.8 it trades +29.8% versus its 200-day average and sits at 89% of its 52-week range ($3–$9).

Aug 26: $8.8 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
+29.8% versus the 200-day line, week 47 of stage 2
Price50-day avg200-day avg
S2S2S1S3S2$10.1$7.8$5.4$3.0$0.6$$9$7Jul 23Apr 24Jan 25Oct 25Aug 26
S2S2S1S3S2$10.1$7.8$5.4$3.0$0.6$$9$7Jul 23Jan 25Aug 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (527 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 16Aug 26

Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved −59% while the S&P 500 moved +263% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-07-31) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

P/E does not price Diversified Healthcare Trust — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. On sales the market values Diversified Healthcare Trust at 1.3× its FY25 revenue of $1.5 B.

With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.

P/E
earnings negative
PEG
n/m
not derivable — 3-year earnings growth unavailable

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: No read

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Diversified Healthcare Trust reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.

Growth, year by year: revenue +2.7% in FY25 Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
12%−109.5%6.5%−109.9%1.5%−110.3%−3.5%−110.8%−8.6%−111.2%%%2.7%−111.1%FY21FY23FY25
12%−109.5%6.5%−109.9%1.5%−110.3%−3.5%−110.8%−8.6%−111.2%%%2.7%−111.1%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue stabilising
RevenueProfitEPS
12%−161%8.8%−162%5.8%−164%2.8%−165%0.0%−167%%%0.7%−161.9%−161.1%Jun 23Sep 24Mar 26
12%−161%8.8%−162%5.8%−164%2.8%−165%0.0%−167%%%0.7%−161.9%−161.1%Jun 23Sep 24Mar 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
−1.4%−2.2%−3.1%−4.0%−4.8%%−3.5%Jun 23Dec 23Sep 24Jun 25Mar 26
−1.4%−2.2%−3.1%−4.0%−4.8%%−3.5%Jun 23Sep 24Mar 26
Revenue growth
Steady high
latest +0.7% · span +0.7% to +10.9%
ROCE
Stuck low
latest −3.5% · span −4.6%–−1.6%

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+2.7%+6.4%
Stock price+169.1%+48.3%+17.1%−8.8%
Revenue YoY (Mar 26)
−5.1%
latest quarter vs a year ago
Revenue 10y
2.8%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

43.9/100 — rank 11 of 17 in REIT - Healthcare Facilities · 55% evidence confidence

Diversified Healthcare Trust scores 43.9 out of 100 against the 17 companies it is compared with in REIT - Healthcare Facilities, ranking 11. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 15.8 + 4.3 + 9.8 + 14 = 43.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if ROA rolls over or gross NPA rises while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Diversified Healthcare Trust reported $0.4 B of revenue in the Mar 26 quarter, −5.1% year on year. Over 4 years it has compounded at 2.8% a year. The last full year, FY25, came in at $1.5 B. The last four reported quarters add to $1.5 B.

FY25 revenue came in at $1.5 B (+2.7% on the year), capping 4 years at 2.8% compound. The latest quarter (Mar 26) printed $0.4 B, −5.1% year on year.

FY25 revenue $1.5 B (+2.7% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
2.8% a year over 4 years
RevenueYoY growth
1.712%1.26.5%0.81.5%0.4−3.5%0.0−8.6%$ B%$2B2.7%FY21FY23FY25
1.712%1.26.5%0.81.5%0.4−3.5%0.0−8.6%$ B%$2B2.7%FY21FY23FY25
Mar 26: $0.4 B (−5.1% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Revenue (quarterly)YoY growth
0.414%0.39.1%0.23.9%0.1−1.3%0.0−6.5%$ B%$0B−5.1%Jun 23Sep 24Mar 26
0.414%0.39.1%0.23.9%0.1−1.3%0.0−6.5%$ B%$0B−5.1%Jun 23Sep 24Mar 26

Pace check: the last four quarters averaged +0.8% growth against the decade's 2.8% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +0.7% over the last 4 quarters against +2.7%/yr over the last 8 — stabilising.

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Diversified Healthcare Trust's operating margin is 0.0% in the Mar 26 quarter, +10.3 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −13.0% to −2.2%. The current quarter is running above every full year in that window.

The latest quarter's operating margin is 0.0%, +10.3 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −13.0%–−2.2%.

Why the margin moved: operating margin went +10.3 pp year on year while gross margin went +3.7 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

FY25: −13.0% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
within a −13.0–−2.2% band over 5 years
operating marginYoY change (pp)
−1.3%0.3%−4.5%−1.1%−7.6%−2.5%−11%−3.8%−14%−5.2%%%−13%−4.3%FY21FY23FY25
−1.3%0.3%−4.5%−1.1%−7.6%−2.5%−11%−3.8%−14%−5.2%%%−13%−4.3%FY21FY23FY25
Mar 26: 0.0% operating margin (+10.3 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
2.3%13%−5.9%4.5%−14%−3.6%−22%−12%−30%−20%%%0%10.3%Jun 23Sep 24Mar 26
2.3%13%−5.9%4.5%−14%−3.6%−22%−12%−30%−20%%%0%10.3%Jun 23Sep 24Mar 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Diversified Healthcare Trust posted a net loss of $0.04 B in the Mar 26 quarter. The full FY25 year was a loss of $0.3 B. That loss is 10.8% of the quarter's revenue. The same quarter a year earlier lost $0.01 B. 12 of the last 12 reported quarters were loss-making.

Mar 26 profit was $−0.0 B, null year on year. On the full year, FY25 printed $−0.3 B (null).

FY25 profit $−0.3 B (null YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
Net profitYoY growth
0.2−109.9%0.1−110.5%−0.1−111.1%−0.3−111.7%−0.4−112.3%$ B%$−0B−111.1%FY21FY23FY25
0.2−109.9%0.1−110.5%−0.1−111.1%−0.3−111.7%−0.4−112.3%$ B%$−0B−111.1%FY21FY23FY25
Mar 26: $−0.0 B (null YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)
0.01−0.03−0.08−0.13−0.17$ B$0BJun 23Sep 24Mar 26
0.01−0.03−0.08−0.13−0.17$ B$0BJun 23Sep 24Mar 26
08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Diversified Healthcare Trust's cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $−0.0 B of operating cash against $−0.3 B of profit. After $0.1 B of capital spending, $−0.2 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.

FY25: operating cash of $−0.0 B against reported profit of $−0.3 B, leaving free cash of $−0.2 B after $0.1 B of capital spending.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO $−0.0 B vs profit $−0.3 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution. FY22 reflects an acquisition year — point shown clipped.
Operating cashNet profitFree cash
0.20.1−0.1−0.3−0.4$ B$0B$−0B$−0BFY21FY23FY25
0.20.1−0.1−0.3−0.4$ B$0B$−0B$−0BFY21FY23FY25
Mar 26: operating cash $0.0 B Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)100%
0.06101.2%0.03100.6%0.00100.0%−0.0399.4%−0.0698.8%$ B%$0BJun 23Sep 24Mar 26
0.06101.2%0.03100.6%0.00100.0%−0.0399.4%−0.0698.8%$ B%$0BJun 23Sep 24Mar 26

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Diversified Healthcare Trust does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $1.0 B over the last 3 years. Averaged over those years that is 21.6% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $1.0 B over the last 3 fiscal years.

FY25: capex $0.1 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
0.40.30.20.10.0$ B$0BFY21FY23FY25
0.40.30.20.10.0$ B$0BFY21FY23FY25
Mar 26: capex $0.0 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)Free cash
0.080.030.060.000.04−0.030.02−0.070.00−0.10$ B$ B$0B$0BJun 23Sep 24Mar 26
0.080.030.060.000.04−0.030.02−0.070.00−0.10$ B$ B$0B$0BJun 23Sep 24Mar 26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

Diversified Healthcare Trust earns a ROE of −17% in FY25. That is up from a trough of −19% in FY24. Return on invested capital clears the cost of that capital by −11.7 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −18.8% net margin on 0.35× asset turns.

FY25 ROE is −17%, recovered from a FY24 trough of −19% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY25): −18.8% net margin × 0.35× asset turns × 2.61× balance-sheet leverage ≈ −17.2% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: −0.8% − 10.9% = a −11.7 pp spread. The 10.9% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

FY25: ROE −17% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included. Dashed line = the 10.9% cost of capital used on this page.
the climb back from FY24's −19%
ROEROIC (annual)WACC
13%4.6%−4.0%−13%−21%%−17.4%−5%FY21FY23FY25
13%4.6%−4.0%−13%−21%%−17.4%−5%FY21FY23FY25
Mar 26: ROIC −3.9% (TTM) vs WACC 10.9% Trailing-twelve-month ROIC and ROE, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)WACC
13%4.9%−3.5%−12%−20%%−3.9%−17%Jun 23Sep 24Mar 26
13%4.9%−3.5%−12%−20%%−3.9%−17%Jun 23Sep 24Mar 26
11 · Dividend

Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.

Diversified Healthcare Trust paid $0.04 per share over the last four reported quarters. The most recent declaration was $0.01 for Mar 26. Against the current price of $8.8 that is a trailing yield of 0.45%, measured on dividends already paid rather than on a forecast.

Diversified Healthcare Trust paid $0.04 per share across the last four reported quarters, most recently $0.01 for Mar 26. Against the current price of $8.8 the trailing twelve months work out to 0.45% — trailing dividends measured against today's price, not a forward estimate.

Dividend per share by quarter Declared dividend per share, $ B, per reported quarter. 12 quarters on file.
latest $0.01 (Mar 26)
Dividend per share
0.0110.0080.0050.0030.000$ B$0BJun 23Dec 23Sep 24Jun 25Mar 26
0.0110.0080.0050.0030.000$ B$0BJun 23Sep 24Mar 26
12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Diversified Healthcare Trust carries total debt of $2.4 B against shareholder equity of $1.6 B as of Mar 26, a debt-to-equity of 1.48. On the annual view that ratio went from 1.38 in FY21 to 1.71 in FY25. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of $2.4 B against shareholder equity of $1.6 B — a debt-to-equity of 1.48. On the annual view, debt-to-equity went from 1.38 (FY21) to 1.71 (FY25). Read the returns on this page with that leverage in mind.

FY25: debt $2.9 B at 1.71× equity Total debt by fiscal year, $ B (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
4.01.8×3.01.6×2.01.4×1.01.2×0.01.0×$ B×$3B1.71×FY21FY23FY25
4.01.8×3.01.6×2.01.4×1.01.2×0.01.0×$ B×$3B1.71×FY21FY23FY25
Mar 26: debt $2.4 B, debt-to-equity 1.48 Total debt per quarter, $ B (bars); debt-to-equity, × (line). Last 12 quarters.
Total debt (quarterly)Debt-to-equity
3.21.8×2.41.6×1.61.4×0.81.2×0.01.0×$ B×$2B1.48×Jun 23Sep 24Mar 26
3.21.8×2.41.6×1.61.4×0.81.2×0.01.0×$ B×$2B1.48×Jun 23Sep 24Mar 26
13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

6.7% of Diversified Healthcare Trust's tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 7.1 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 6.7% of the float is sold short, and at typical trading volumes it would take about 7.1 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
6.7%
of the tradable float
Days to cover
7.1
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Diversified Healthcare Trust: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

15 · Related companies · REIT - Healthcare Facilities
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Strawberry Fields REIT, Inc.STRW 59.2/100Mixed-positive evidence70% evidence TURNING 19.7/35 Income 26.4% · PAT 28.6% 71% evidence 20.4/25 ROA 2.6% · ROE 37.4% · GNPA — 68% evidence 7.8/20 P/BV 13.04× · P/BV÷ROE 0.35 70% evidence 11.3/20 RS sector 0.6% · RS bench -0.2% · 1Y 33.5%3 of 12 weeks ahead 70% evidence
Exact sum: 19.7 + 20.4 + 7.8 + 11.3 = 59.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Omega Healthcare Investors, Inc.OHI 54.3/100Mixed-positive evidence60% evidence ASLEEP 20.3/35 Income — · PAT — 26% evidence 17.5/25 ROA 1.8% · ROE 7% · GNPA — 68% evidence 8.0/20 P/BV 2.65× · P/BV÷ROE 0.38 70% evidence 8.5/20 RS sector -2.3% · RS bench -3.2% · 1Y 22%1 of 12 weeks ahead 100% evidence
Exact sum: 20.3 + 17.5 + 8 + 8.5 = 54.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3LTC Properties, Inc.LTC 54.2/100Mixed-positive evidence76% evidence BASING 26.3/35 Income 53.3% · PAT 39.1% 71% evidence 15.7/25 ROA 1.8% · ROE 2.1% · GNPA — 68% evidence 7.6/20 P/BV 1.67× · P/BV÷ROE 0.79 70% evidence 4.6/20 RS sector -6.4% · RS bench -7.2% · 1Y 7.4%1 of 12 weeks ahead 100% evidence
Exact sum: 26.3 + 15.7 + 7.6 + 4.6 = 54.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -6.4% and the one-year return is 7.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
4CareTrust REIT, Inc.CTRE 52.7/100Mixed-positive evidence76% evidence ASLEEP 22.8/35 Income 58.2% · PAT 100% 71% evidence 16.5/25 ROA 2% · ROE 2.2% · GNPA — 68% evidence 6.9/20 P/BV 2.01× · P/BV÷ROE 0.91 70% evidence 6.5/20 RS sector -2.1% · RS bench -3% · 1Y 24.1%1 of 12 weeks ahead 100% evidence
Exact sum: 22.8 + 16.5 + 6.9 + 6.5 = 52.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -2.1% and the one-year return is 24.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
5Welltower Inc.WELL 49.5/100Mixed-negative evidence60% evidence BREAKING OUT 16.9/35 Income — · PAT — 26% evidence 10.8/25 ROA 0.9% · ROE 1.1% · GNPA — 68% evidence 4.3/20 P/BV 3.52× · P/BV÷ROE 3.2 70% evidence 17.5/20 RS sector 5.9% · RS bench 4.8% · 1Y 37.8%2 of 12 weeks ahead 100% evidence
Exact sum: 16.9 + 10.8 + 4.3 + 17.5 = 49.5 · Decision use: Price leads the evidence: RS versus the benchmark is 4.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
6Universal Health Realty Income TrustUHT 47.5/100Mixed-negative evidence60% evidence BASING 18.7/35 Income — · PAT — 26% evidence 15.9/25 ROA 1.6% · ROE 3.8% · GNPA — 68% evidence 5.5/20 P/BV 4.23× · P/BV÷ROE 1.11 70% evidence 7.4/20 RS sector -6.4% · RS bench -7.2% · 1Y 9%0 of 12 weeks ahead 100% evidence
Exact sum: 18.7 + 15.9 + 5.5 + 7.4 = 47.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
7Healthpeak Properties, Inc.DOC 47.0/100Mixed-negative evidence76% evidence BREAKING OUT 10.5/35 Income 2.7% · PAT -18.2% 71% evidence 9.4/25 ROA 0.4% · ROE 2.2% · GNPA — 68% evidence 7.9/20 P/BV 1.46× · P/BV÷ROE 0.66 70% evidence 19.2/20 RS sector 6.9% · RS bench 6.1% · 1Y 27.5%9 of 12 weeks ahead 100% evidence
Exact sum: 10.5 + 9.4 + 7.9 + 19.2 = 47 · Decision use: Price leads the evidence: RS versus the benchmark is 6.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
8National Health Investors, Inc.NHI 45.6/100Mixed-negative evidence76% evidence BASING 17.6/35 Income 17.2% · PAT 5% 71% evidence 16.8/25 ROA 1.8% · ROE 2.7% · GNPA — 68% evidence 6.4/20 P/BV 2.59× · P/BV÷ROE 0.96 70% evidence 4.8/20 RS sector -14.3% · RS bench -15% · 1Y -0.5%0 of 12 weeks ahead 100% evidence
Exact sum: 17.6 + 16.8 + 6.4 + 4.8 = 45.6 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
9Ventas, Inc.VTR 45.4/100Mixed-negative evidence60% evidence ASLEEP 19.4/35 Income — · PAT — 26% evidence 10.2/25 ROA 1.1% · ROE 0.5% · GNPA — 68% evidence 3.4/20 P/BV 3.11× · P/BV÷ROE 6.22 70% evidence 12.4/20 RS sector 2.4% · RS bench 1.4% · 1Y 32.5%2 of 12 weeks ahead 100% evidence
Exact sum: 19.4 + 10.2 + 3.4 + 12.4 = 45.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10American Healthcare REIT, Inc.AHR 44.3/100Mixed-negative evidence67% evidence TURNING 18.1/35 Income 12.2% · PAT — 45% evidence 8.4/25 ROA 0.8% · ROE 0.8% · GNPA — 68% evidence 4.4/20 P/BV 2.57× · P/BV÷ROE 3.22 70% evidence 13.4/20 RS sector 2.4% · RS bench 1.4% · 1Y 34.5%3 of 12 weeks ahead 100% evidence
Exact sum: 18.1 + 8.4 + 4.4 + 13.4 = 44.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11Diversified Healthcare Trustthis pageDHC 43.9/100Thin evidence · provisional55% evidence FADING 15.8/35 Income 0.4% · PAT — 45% evidence 4.3/25 ROA -0.1% · ROE -2.4% · GNPA — 68% evidence 9.8/20 P/BV 0.99× · P/BV÷ROE — 10% evidence 14.0/20 RS sector 28% · RS bench 26.1% · 1Y 161.9%11 of 12 weeks ahead 100% evidence
Exact sum: 15.8 + 4.3 + 9.8 + 14 = 43.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
12Sila Realty Trust, Inc.SILA 43.7/100Mixed-negative evidence70% evidence 15.4/35 Income 9.7% · PAT -71.4% 71% evidence 9.2/25 ROA 1% · ROE 0.3% · GNPA — 68% evidence 4.1/20 P/BV 0.98× · P/BV÷ROE 3.27 70% evidence 15.0/20 RS sector 2.8% · RS bench 8.8% · 1Y 26.4%7 of 7 weeks ahead to 2026-07-02 70% evidence
Exact sum: 15.4 + 9.2 + 4.1 + 15 = 43.7 · Decision use: Price leads the evidence: RS versus the benchmark is 8.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
13Sabra Health Care REIT, Inc.SBRA 42.4/100Mixed-negative evidence76% evidence BASING 18.0/35 Income 12.9% · PAT 11.3% 71% evidence 11.7/25 ROA 1.1% · ROE 1.5% · GNPA — 68% evidence 5.9/20 P/BV 1.74× · P/BV÷ROE 1.16 70% evidence 6.8/20 RS sector -3.8% · RS bench -4.7% · 1Y 10.4%1 of 12 weeks ahead 100% evidence
Exact sum: 18 + 11.7 + 5.9 + 6.8 = 42.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
14Community Healthcare Trust IncorporatedCHCT 39.6/100Mixed-negative evidence61% evidence ASLEEP 16.4/35 Income 5.1% · PAT — 45% evidence 9.4/25 ROA 0.9% · ROE 0.6% · GNPA — 68% evidence 5.5/20 P/BV 1.08× · P/BV÷ROE 1.8 70% evidence 8.3/20 RS sector -2.1% · RS bench -3% · 1Y 22.6%1 of 12 weeks ahead 70% evidence
Exact sum: 16.4 + 9.4 + 5.5 + 8.3 = 39.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
15Medical Properties Trust, Inc.MPT 27.8/100Adverse evidence67% evidence BASING 14.5/35 Income 5.4% · PAT — 45% evidence 5.8/25 ROA -93.4% · ROE 0.7% · GNPA — 68% evidence 7.2/20 P/BV 0.61× · P/BV÷ROE 0.87 70% evidence 0.3/20 RS sector -16.1% · RS bench -16.7% · 1Y 14%0 of 12 weeks ahead 100% evidence
Exact sum: 14.5 + 5.8 + 7.2 + 0.3 = 27.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16Chiron Real Estate Inc.XRN 26.7/100Adverse evidence70% evidence BASING 9.9/35 Income 9.4% · PAT -200% 71% evidence 7.5/25 ROA 0.7% · ROE 0.3% · GNPA — 68% evidence 5.2/20 P/BV 0.88× · P/BV÷ROE 2.92 70% evidence 4.1/20 RS sector -8.9% · RS bench -9.6% · 1Y 6.9%0 of 12 weeks ahead 70% evidence
Exact sum: 9.9 + 7.5 + 5.2 + 4.1 = 26.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
17Healthcare Realty Trust IncorporatedHR 44.1/100Thin evidence · provisional48% evidence FADING 20.4/35 Income — · PAT — 26% evidence 5.2/25 ROA 0.4% · ROE -1% · GNPA — 68% evidence 9.8/20 P/BV 1.64× · P/BV÷ROE — 10% evidence 8.7/20 RS sector -0.4% · RS bench -1.2% · 1Y 21.6%5 of 12 weeks ahead 100% evidence
Exact sum: 20.4 + 5.2 + 9.8 + 8.7 = 44.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Diversified Healthcare Trust's stock price today?

Diversified Healthcare Trust trades at $8.8, +169.1% over the past year. The company is valued at $2.0 B. The stock sits at 89% of its 52-week range of $3–$9, +29.8% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 47 weeks in. — as of 5 August 2026.

What were Diversified Healthcare Trust's latest quarterly results?

Diversified Healthcare Trust reported revenue of $0.4 B and a net loss of $0.0 B for the Mar 26 quarter. Earnings per share were $−0.18. The operating margin was 0.0%, 10.3 pp higher than a year earlier. — as of 5 August 2026.

What is Diversified Healthcare Trust's revenue?

Diversified Healthcare Trust reported revenue of $0.4 B in the Mar 26 quarter, −5.1% year on year. For the full FY25 fiscal year, revenue was $1.5 B (+2.7%). Over the last 4 years revenue compounded at 2.8% a year. — as of 5 August 2026.

What is Diversified Healthcare Trust's profit?

Diversified Healthcare Trust earned $−0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $−0.3 B. The operating margin ran 0.0% in the latest quarter. — as of 5 August 2026.

What is Diversified Healthcare Trust's market cap?

Diversified Healthcare Trust's market capitalisation is $2.0 B at a stock price of $8.8. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.

Does Diversified Healthcare Trust pay a dividend?

Yes — Diversified Healthcare Trust declared $0.01 per share for Mar 26, and $0.04 per share across the last four reported quarters. — as of 5 August 2026.

What is Diversified Healthcare Trust's dividend per share?

Diversified Healthcare Trust's most recently declared dividend is $0.01 per share for Mar 26, giving $0.04 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.

What is Diversified Healthcare Trust's dividend yield?

Diversified Healthcare Trust's trailing dividend yield is 0.45%: $0.04 declared per share across the last four reported quarters, against a share price of $8.8. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.

How is Diversified Healthcare Trust performing?

Diversified Healthcare Trust is in a confirmed uptrend, 47 weeks in. Against the S&P 500 it has been behind on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 5 August 2026.

Is Diversified Healthcare Trust in an uptrend?

Yes — the price is in a confirmed uptrend (week 47 of stage 2), trading +29.8% versus its 200-day average and at 89% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.

Is Diversified Healthcare Trust beating the market?

Not lately — on a trailing-13-week view Diversified Healthcare Trust is currently behind the S&P 500 (1 week and counting; last ahead the week of 2026-07-31), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved −59% against the S&P 500's +263% — behind the index over the full window. — as of 5 August 2026.

Will Diversified Healthcare Trust's stock price go up?

This page publishes no price forecast for Diversified Healthcare Trust. What it measures instead: the stock price is $8.8, the price is in a confirmed uptrend 47 weeks in. Direction is not something this site claims to know. — as of 5 August 2026.

Is the market betting against Diversified Healthcare Trust?

Somewhat — short interest is 6.7% of Diversified Healthcare Trust's tradable float, about 7.1 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.

Does Diversified Healthcare Trust have too much debt?

It carries real leverage — Diversified Healthcare Trust's debt-to-equity is 1.52. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.

What is Diversified Healthcare Trust's capex?

Diversified Healthcare Trust spent $1.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.1 B. — as of 5 August 2026.

What is Diversified Healthcare Trust's cash flow?

Diversified Healthcare Trust generated $−0.0 B of operating cash flow in FY25 and $−0.2 B of free cash flow after $0.1 B of capital spending. Reported profit that year was $−0.3 B, so operating cash ran ahead of profit. — as of 5 August 2026.

Where is Diversified Healthcare Trust in its business cycle?

Diversified Healthcare Trust's FY25 operating margin was −13.0%, against a 5-year band of −13.0%–−2.2%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 0.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.

What could break the Diversified Healthcare Trust story?

Biggest watch item: the price is already 47 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.

Is Diversified Healthcare Trust a stock worth studying right now?

This is not investment advice. The machine read: Diversified Healthcare Trust's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI